Valuation: Bioventix PLC

Market Cap 78.37M 106M 91.74M 85.75M 148M 10.11B 150M 1.01B 395M 5.06B 398M 389M 16.84B P/E 2026 *
11.2x
P/E 2027 * -
Enterprise Value 73.48M 99.36M 86.01M 80.4M 138M 9.48B 141M 943M 370M 4.74B 373M 365M 15.79B EV / Sales 2026 *
5.88x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
10%
Yield 2027 * -
1 day-0.40%
1 week-1.06%
Current month-1.06%
1 month-6.62%
3 months-12.12%
6 months-14.63%
Current year-21.57%
1 week 1,470
Extreme 1470
1,550
1 month 1,470
Extreme 1470
1,650
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,550
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 23/12/2003
Director of Finance/CFO 67 01/07/2020
Director TitleAgeSince
Director/Board Member 67 25/11/2010
Chairman 66 01/11/2004
Director/Board Member 67 01/07/2020
Date Insider Type Main position Quantity % Market Cap.
4/20/26 A Free

Chief Financial Officer

9,967 0.1908%
11/26/25 A Buy

Chief Financial Officer

150 0.0029%
11/4/25 A Buy

Chief Executive Officer

875 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-1.06%-37.88%-60.68% 106M
-0.22%+3.31%+6.21%+16.14% 50.03B
+0.89%+13.44%+491.34%+594.30% 44.36B
+3.08%+14.42%+24.57%+81.39% 40.82B
+1.38%+3.70%+34.54%+9.11% 39.83B
+0.85%+10.32%+21.22%+47.64% 32.51B
+0.08%+5.00% - - 16.85B
+1.99%+5.08%+38.70%+125.08% 16.81B
-0.63%+1.13%+5.04%+20.83% 14.05B
+3.56%+19.98%+86.23%+27.29% 13.22B
Average +1.06%+402.13%+74.44%+95.68% 26.86B
Weighted average by Cap. +1.15%+295.50%+107.39%+139.65%

Financials

2026 *2027 *
Net sales 12.5M 16.9M 14.63M 13.68M 23.56M 1.61B 23.92M 160M 62.93M 806M 63.47M 62.08M 2.69B -
Net income 7.11M 9.62M 8.33M 7.78M 13.4M 917M 13.61M 91.25M 35.81M 459M 36.11M 35.32M 1.53B -
Net Debt -4.89M -6.62M -5.73M -5.35M -9.22M -631M -9.37M -62.79M -24.64M -316M -24.85M -24.31M -1.05B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
11/08/26 GBX 1,494.00 -0.40% 2,105
10/08/26 GBX 1,500.00 -0.66% 5,248
07/08/26 GBX 1,510.00 +0.67% 5,875
06/08/26 GBX 1,500.00 0.00% 2,922
05/08/26 GBX 1,500.00 -0.66% 13,162
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock